No Data
US Stock MarketDetailed Quotes
BLRX BioLine Rx
Watchlist
1.690
-0.090-5.06% Close 12/11 16:00 ET
1.650-0.040-2.37%
Post 17:28 ET
1.815High1.590Low391.13KVolume
1.740Open1.780Pre Close659.55KTurnover0.60%Turnover RatioLossP/E (TTM)122.07MMarket Cap2.53052wk HighLossP/E (Static)72.23MShares0.54552wk Low9.29P/B110.05MFloat Cap103.050Historical High--Dividend TTM65.12MShs Float0.545Historical Low--Div YieldTTM12.64%Amplitude1.686Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About BioLine Rx Company
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.
News
HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $21 price target.
BioLine Rx Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 11/20/2023 1204.35% HC Wainwright & Co. → $21 Reiterates Buy → Buy 09/15/2023 1204.35% HC Wainwright & Co.
Bioline RX Receives Buy Rating Despite Lower Than Expected Q3 Results: Expansions, Partnerships, and Promising Clinical Trials Signal Future Growth